Pancreatic Cancer Research

ResearcherMedical University of GrazNo recent work listed

Joanna Szkandera

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2217-893X; OpenAlex author ID A5040602619. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2013: 4 papers · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper

Papers 11

  1. Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12051154↗
  2. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer. Co-author DOI 10.1515/cclm-2018-0016↗
  3. Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis. First author DOI 10.1007/s00508-018-1383-3↗
  4. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. Co-author DOI 10.1136/jclinpath-2014-202451↗
  5. The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. First author DOI 10.1515/cclm-2014-0447↗
  6. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Co-author DOI 10.1038/bjc.2013.701↗
  7. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. First author DOI 10.1371/journal.pone.0104730↗
  8. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Co-author DOI 10.1038/bjc.2013.332↗
  9. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer Co-author DOI 10.1038/bjc.2013.591↗
  10. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. Co-author DOI 10.1136/jclinpath-2012-201394↗
  11. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0078225↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Stotz · 11 shared papers, 2013–2020 · strength 0.56
  2. Armin Gerger · 11 shared papers, 2013–2020 · strength 0.56
  3. Martin Pichler Pichler · 11 shared papers, 2013–2020 · strength 0.56
  4. Peter Kornprat · 11 shared papers, 2013–2020 · strength 0.56
  5. Konstantin Schlick · 3 shared papers, 2018–2020 · strength 0.26
  6. Gerald Höefler · 6 shared papers, 2013–2015 · strength 0.21
  7. Eva Valentina Klocker · 2 shared papers, 2019–2020 · strength 0.19
  8. Anna Lena Lembeck · 2 shared papers, 2018–2019 · strength 0.16
  9. Jakob Michael Riedl · 1 shared paper, 2020 · strength 0.10
  10. Dominik Andreas Barth · 1 shared paper, 2020 · strength 0.10
  11. D. Reitz · 2 shared papers, 2014–2015 · strength 0.09
  12. Eva Asamer · 1 shared paper, 2018 · strength 0.07
  13. Wael Al Zoughbi · 2 shared papers, 2013 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.